Medtronic

The biotech IPO window is opening, but big pharma M&A is still driving the pace of biopharma dealmaking due to pressure to replenish drug pipelines before major patent expirations later this decade. Top bankers shared this insight with CNBC, highlighting the current state of the biopharma industry. This trend is expected to continue as companies seek to replace expiring patents with new treatments.

Impact: The ongoing M&A activity in the biopharma sector is likely to impact the valuations of companies in this space, particularly those with promising pipelines or near-term patent expirations.

Not investment advice